CRANBURY, N.J., Nov. 27 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that it will host an "R&D Day" meeting on December 19, 2007 from 4:30 to 7:00 PM at the Four Seasons Hotel in New York City. The presentation will include a summary of the results of the Phase 2 clinical trials performed for Amigal(TM) (migalastat hydrochloride) for Fabry disease as well as an update and detailed review on other research and development programs at the company.
A live audio web cast of the presentation will be available to all interested parties through the Investors section of Amicus' website at http://www.amicustherapeutics.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast.
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has two product candidates in Phase II clinical trials, Amigal(TM) for the treatment of Fabry disease and Plicera(TM) for the treatment of Gaucher disease. The Company announced positive data from Phase I clinical trials of AT2220 for the treatment of Pompe disease in October 2007.
|SOURCE Amicus Therapeutics|
Copyright©2007 PR Newswire.
All rights reserved